Dr. Gupta discusses avelumab first-line maintenance treatment for advanced urothelial carcinoma

“The key message from this abstract is that the time duration for starting avelumab [Bavencio] maintenance didn't really affect the outcomes,” says Shilpa Gupta, MD.

In this video, Shilpa Gupta, MD, discusses key findings from the study, "Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC) in the JAVELIN Bladder 100 trial: Subgroup analysis by duration of treatment-free interval (TFI) from end of chemotherapy to start of maintenance,” which was presented at the 2021 ASCO annual meeting. Gupta is the Director of the Genitourinary Medical Oncology at Taussig Cancer Institute and Co-Leader of the Genitourinary Oncology Program at Cleveland Clinic.

Related Videos
Matthew J. Ziegelmann, MD, answers a question during a Zoom video interview
Dr. Smita De in an interview with Urology Times
Doctor receiving patient in office | Image Credit © Africa Studio - stock.adobe.com
Alisa J. Stephens-Shields, PhD, answers a question during a Zoom video interview
Blurred interior of hospital | Image Credit: © jakkapan - stock.adobe.com
Dr. David Sheyn in an interview with Urology Times
Avinash Maganty, MD, answers a question during a Zoom video interview
blur image background of corridor in hospital or clinic image | Image Credit:  © whyframeshot - stock.adobe.com
Rachel Pope, MD, MPH, answers a question during a Zoom interview
Related Content
© 2023 MJH Life Sciences

All rights reserved.